Neuroleptic malignant syndrome, a rare but potentially fatal side effect of antipsychotic medications, has often proven refractory to conventional antiparkinsonian medications. The authors report a dramatic response of this syndrome to the dopamine agonist bromocriptine mesylate in a patient receiving fluphenazine decanoate.
No takes yet. Share an insight, caveat, or question.
Zubenko et al. (1983) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: